Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Rina Plattner
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04903119CT.gov Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma | — | Recruiting | — | — | — |
NCT01168050CT.gov Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nilotinib (this asset) | Rina Plattner | P2 | CCC · 55 |
| Cediranib | M.D. Anderson Cancer Center | P2 | BBB |
| Dacarbazine | Shanghai Junshi Bioscience Co., Ltd. | P4 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Nivolumab | Bristol-Myers Squibb | P4 | BB |
| Montanide Isa 51 | Ludwig Institute for Cancer Research | P2 | BB |
| Therapeutic Autologous Lymphocytes | Fred Hutchinson Cancer Center | P2 | BB |
| TIL | East Metropolitan Health Service, Australia | P2 | BB |
| Ipilimumab | NYU Langone Health | P4 | BB |
+42 more in the Metastatic Melanoma cohort
Other indications for Nilotinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) | — | P2 | BBB · 74 |
| Chronic Myeloid Leukemia | — | P4 | BBB · 73 |
| Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | — | P2 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nilotinib in Metastatic Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nilotinib-metastatic-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →